Published in Int J Chron Obstruct Pulmon Dis on January 01, 2006
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 0.93
A score to predict short-term risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis (2015) 0.88
Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci (2011) 0.83
Comparison and optimal use of fixed combinations in the management of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.76
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study. Int J Chron Obstruct Pulmon Dis (2016) 0.76
Economic burden of asthma in Abu Dhabi: a retrospective study. Clinicoecon Outcomes Res (2014) 0.75
Pharmacological treatment response according to the severity of symptoms in patients with chronic obstructive pulmonary disease. J Thorac Dis (2015) 0.75
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis (1992) 15.92
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med (2003) 6.82
Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax (2004) 6.41
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet (2005) 5.94
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.99
Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J (2004) 2.80
Chronic obstructive pulmonary disease. Lancet (2003) 2.64
The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J (2004) 2.14
Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 2.03
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J (2003) 1.70
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med (2004) 8.39
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. COPD (2004) 3.14
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol (2013) 3.03
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax (2010) 2.86
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest (2007) 2.67
Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation (2010) 2.45
Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med (2003) 2.45
Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest (2003) 2.44
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med (2012) 2.27
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med (2010) 2.09
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax (2007) 2.05
Variability of a closed, rebreathing setup for multiple breath wash-out testing in children. Pediatr Pulmonol (2012) 2.03
Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration (2012) 1.99
Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm (2011) 1.93
Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest (2006) 1.85
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest (2007) 1.79
Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol (2009) 1.79
Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol (2011) 1.69
Identification and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol (2004) 1.66
The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. Am J Respir Crit Care Med (2006) 1.65
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol (2008) 1.59
The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax (2011) 1.54
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol (2014) 1.51
Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res (2011) 1.51
Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD (2004) 1.46
Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol (2002) 1.45
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med (2010) 1.33
Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol (2005) 1.27
Cardiovascular events in patients with COPD: TORCH study results. Thorax (2010) 1.25
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health (2010) 1.21
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med (2014) 1.14
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. Int Arch Allergy Immunol (2005) 1.12
Murine TLR4 is implicated in cigarette smoke-induced pulmonary inflammation. Int Arch Allergy Immunol (2006) 1.12
Noise, artifact, and oversensing related inappropriate ICD shock evaluation: ALTITUDE noise study. Pacing Clin Electrophysiol (2012) 1.09
The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation. COPD (2012) 1.09
Short-term cigarette smoke exposure enhances allergic airway inflammation in mice. Am J Respir Crit Care Med (2005) 1.09
Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J (2012) 1.09
Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res (2011) 1.08
Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res (2014) 1.06
Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD (2012) 1.06
Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA (2002) 1.05
Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest (2010) 1.04
Derivation of normative data for the COPD assessment test (CAT). Respir Res (2014) 1.02
Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest (2013) 1.02
COPD and disease-specific health status in a working population. Respir Res (2013) 1.00
Signaling noncomprehension of language: a comparison of fragile X syndrome and Down syndrome. Am J Ment Retard (2008) 0.98
Validity of the COPD assessment test translated into local languages for Asian patients. Chest (2013) 0.94
Health-related quality of life in patients with chronic respiratory failure after long-term mechanical ventilation. Respir Med (2005) 0.94
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 0.93
Gene expression and immunolocalization of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis. Am J Respir Cell Mol Biol (2002) 0.93
Prescribing patterns in premenstrual syndrome. BMC Womens Health (2002) 0.92
Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med (2004) 0.92
Repeatability of a Rasch model of the AQ20 over five assessments. Qual Life Res (2006) 0.92
The role of neural inflammation in asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci (2003) 0.91
Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol (2003) 0.90
Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol (2005) 0.89
Costs of asthma among US working adults. Am J Manag Care (2011) 0.89
Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures. Curr Med Res Opin (2007) 0.88
Brazilian version of airways questionnaire 20: a reproducibility study and correlations in patients with COPD. Respir Med (2004) 0.87
Assessment of dyspnea in asthma: validation of The Dyspnea-12. J Asthma (2011) 0.86
Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol (2010) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. Ann Am Thorac Soc (2015) 0.85
Efficacy of flow- vs impedance-guided autoadjustable continuous positive airway pressure: a randomized cross-over trial. Chest (2004) 0.84
The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness. J Allergy Clin Immunol (2002) 0.83
A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011. Int J Chron Obstruct Pulmon Dis (2013) 0.83
The role of the tachykinin NK1 receptor in airway changes in a mouse model of allergic asthma. J Allergy Clin Immunol (2004) 0.82
Effect of combining salmeterol and fluticasone on the progression of airway remodeling. Am J Respir Crit Care Med (2002) 0.82
Impact of shock energy and ventricular rhythm on the success of first shock therapy: the ALTITUDE first shock study. Heart Rhythm (2013) 0.82
A critique of Rasch analysis using the Dyspnoea-12 as an illustrative example. J Adv Nurs (2011) 0.81
Comfort and pressure profiles of two auto-adjustable positive airway pressure devices: a technical report. Respir Med (2003) 0.80
Evaluation of male COPD patients' health status by proxies. Respir Med (2006) 0.80
Impact of symptoms of anxiety and depression on COPD Assessment Test scores. Eur Respir J (2013) 0.79
The effects of weak genetic perturbations on the transcriptome of the wing imaginal disc and its association with wing shape in Drosophila melanogaster. Genetics (2011) 0.79
GOLD COPD categories are not fit for purpose in primary care--authors' reply. Lancet Respir Med (2013) 0.79
Probing phenylalanine/adenine pi-stacking interactions in protein complexes with explicitly correlated and CCSD(T) computations. J Phys Chem B (2008) 0.79
Phase II study of tight glycaemic control in COPD patients with exacerbations admitted to the acute medical unit. BMJ Open (2011) 0.79
COPD: functional status, health status and primary care. Prim Care Respir J (2011) 0.79
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur Respir J (2012) 0.78
Does change in device detected frequency of non-sustained or diverted episodes serve as a marker for inappropriate shock therapy? Analyses from the INTRINSIC RV and ALTITUDE-REDUCES Trials. Europace (2014) 0.78
Effectiveness of early budesonide intervention in Caucasian versus Asian patients with asthma: 3-year results of the START study. Respirology (2006) 0.78
Triple therapy for chronic obstructive pulmonary disease: trials catching up with clinical practice? Am J Respir Crit Care Med (2009) 0.77
Changes in thresholds for intracortical excitability in chronic stroke: more than just altered intracortical inhibition. Restor Neurol Neurosci (2013) 0.77